Disease Type Segment Analysis: Wet AMD (Largest Segment) vs Dry AMD (Fastest-Growing Segment)

The wet AMD segment dominated the age-related macular degeneration treatment market with a 91.24% share in 2026. Its leadership is primarily attributed to the availability of well-established therapeutic options that effectively slow disease progression and help preserve vision. The severe and rapidly progressive nature of wet age-related macular degeneration often requires timely medical intervention, resulting in high treatment uptake. Continuous improvements in retinal therapies, increased disease awareness, and broader access to ophthalmic care have further reinforced the segment's dominant position.

The dry AMD segment is expected to witness the fastest growth during the forecast period as research efforts continue to expand treatment options for a condition that has historically had limited therapeutic alternatives. Greater emphasis on early diagnosis, increasing adoption of advanced retinal imaging technologies, and the emergence of novel therapeutic approaches are expected to improve disease management. Growing awareness regarding routine eye examinations among aging populations is also supporting increased demand for treatment in this segment.

Age Group Segment Analysis: 65–74 Years (Largest Segment) vs 75 and Above (Fastest-Growing Segment)

Holding the largest share of the age-related macular degeneration treatment market, the 65–74 years age group accounted for 56.92% in 2026. Individuals within this age range represent a substantial patient population requiring regular ophthalmic monitoring and therapeutic intervention as the incidence of retinal degeneration increases with advancing age. Improved healthcare access, greater awareness of vision preservation, and routine screening practices contribute to sustained treatment demand within this demographic.

The 75 and above age group is projected to register the fastest growth during the forecast period due to the increasing prevalence and progression of retinal disorders among the oldest population. Longer life expectancy, expanding geriatric healthcare services, and greater emphasis on maintaining quality of life are encouraging earlier diagnosis and more consistent treatment among elderly patients. These factors are expected to accelerate demand within this age category.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs E-commerce (Fastest-Growing Segment)

The hospital pharmacies segment held the largest share of 52.47% in 2026. Hospital pharmacies remain the primary distribution channel for age-related macular degeneration therapies because many treatments require specialist supervision, controlled storage, and administration within clinical settings. Their close integration with ophthalmology departments ensures timely access to prescription therapies while supporting continuity of patient care and treatment monitoring.

In the age-related macular degeneration treatment market, the e-commerce segment is anticipated to experience the fastest growth during the forecast period. The increasing adoption of digital healthcare services, rising utilization of online pharmacy platforms, and growing preference for convenient medicine procurement are driving this expansion. Improved home delivery services and wider access to prescription refill platforms are further strengthening the role of e-commerce in supporting long-term treatment adherence.